← Eichor
Study identifier: NCT05335187 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Hybrid Micro-macro Electrodes in Patients With Epilepsy

Condition: Epilepsy  ·  Sponsor: Pierre Mégevand

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The aim of the MicroEPI study is to know whether it is possible to use safely a medical device (a micro-electrode) that allows recording the activity of neurons in the human brain. Patients who suffer from drug-resistant epilepsy and who are candidates to epilepsy surgery to alleviate their condition sometimes require the implantation of intracranial EEG electrodes for a few weeks, in order to determine as best as possible which region of the brain to operate on. In the MicroEPI study, some of these electrodes will also comprise micro-electrodes, allowing us to record the activity of the patients' neurons during their epileptic seizures.

This description comes directly from the study's public registry record.

Talk to the study team

Pierre Mégevand, MD, PhD  ·  +41 22 379 53 88  ·  pierre.megevand@unige.ch

Always discuss trial participation with your own doctor first.

Locations (2)

Inselspital BernBern, Canton of Bern, SwitzerlandRecruiting
Hôpitaux Universitaires de GenèveGeneva, CH, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05335187